BREAKING NEWS

FDA Grants Approval to Teclistamab Combo in RRMM

The Commissioner’s National Priority Voucher has been granted by the FDA to teclistamab plus daratumumab hyaluronidase-fihj in relapsed/refractory multiple myeloma.